相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study
Takafumi Koyauchi et al.
THORAX (2021)
Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting
Motoyasu Kato et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation
Yasuhiko Koga et al.
ENVIRONMENTAL SCIENCE & TECHNOLOGY LETTERS (2021)
Long-term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®-ON
Jin Woo Song et al.
RESPIROLOGY (2020)
Treatment with Tumor Necrosis Factor-α Inhibitors, History of Allergy, and Hypercalcemia Are Risk Factors of Immune Reconstitution Inflammatory Syndrome in HIV-Negative Pulmonary Tuberculosis Patients
Yoshimasa Hachisu et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Prognostic nutritional index as a predictor of mortality in nontuberculous mycobacterial lung disease
Yoshimasa Hachisu et al.
JOURNAL OF THORACIC DISEASE (2020)
Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis
Yasutaka Hirasawa et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2020)
Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study
Paolo Cameli et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2020)
Possible Serological Markers to Predict Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Yoshimasa Hachisu et al.
MEDICINA-LITHUANIA (2019)
Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
Yasuhiko Koga et al.
MEDICINA-LITHUANIA (2019)
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
E. Bargagli et al.
PULMONOLOGY (2019)
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON
Bruno Crestani et al.
LANCET RESPIRATORY MEDICINE (2019)
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment
Stefania Cerri et al.
RESPIRATORY MEDICINE (2019)
Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
Motoyasu Kato et al.
SCIENTIFIC REPORTS (2019)
Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors
Coralynn Sack et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Low starting-dosage of nintedanib for the reduction of early termination
Satoshi Ikeda et al.
RESPIRATORY INVESTIGATION (2019)
The Efficacy and Safety Long-term Pirfenidone Therapy in Patients with Idiopathic Pulmonary Fibrosis
Kazumasa Ogawa et al.
INTERNAL MEDICINE (2018)
Diagnosis of Idiopathic Pulmonary Fibrosis An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Ganesh Raghu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
The Role of Occupational and Environmental Exposures in the Pathogenesis of Idiopathic Pulmonary Fibrosis: A Narrative Literature Review
Samuel P. Trethewey et al.
MEDICINA-LITHUANIA (2018)
South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Shaney L. Barratt et al.
FRONTIERS IN PHARMACOLOGY (2018)
Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials
Arata Azuma et al.
RESPIROLOGY (2017)
Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis
Satoshi Ikeda et al.
SCIENTIFIC REPORTS (2017)
Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience
Satoshi Ikeda et al.
RESPIRATORY INVESTIGATION (2017)
Validation of the Japanese disease severity classification and the GAP model in Japanese patients with idiopathic pulmonary fibrosis
Shun Kondoh et al.
RESPIRATORY INVESTIGATION (2016)
Nintedanib in the treatment of idiopathic pulmonary fibrosis
Mariano E. Mazzei et al.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2015)
All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis
Takashi Ogura et al.
RESPIRATORY INVESTIGATION (2015)
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Talmadge E. King et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis A Population-Based Study
Evans R. Fernandez Perez et al.
CHEST (2010)
分享论文
